1. In this retrospective cohort study, nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and mortality associated with coronavirus disease 2019 ...
1. In this trial emulation study, molnupiravir and nirmatrelvir-ritonavir reduced all-cause mortality in vaccinated and unvaccinated hospitalized patients with coronavirus ...
1. All-cause hospitalizations and deaths were reported in 1% of patients in the molnupiravir and usual care groups, with no ...
1. In coronavirus disease 2019 (COVID-19) patients, molnupiravir was associated with earlier and larger reductions of C-reactive protein (CRP) as ...
1. In coronavirus disease 2019 (COVID-19) patients, molnupiravir was associated with earlier and larger reductions of C-reactive protein (CRP) as ...
1. Patients hospitalized with COVID-19 receiving at least one dose of molnupiravir did not show reduced mortality compared to patients ...
